Physician profile
Andrew Kim
NPI 1699858993
$4,634.23
in general payments reported to CMS, 2019-2025
22 companies · $609 in 2025
The $609 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $1,093 · 2021: $1,112 · 2022: $93.24 · 2023: $266 · 2024: $257 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,132.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $954.83 | 2019-2025 | Farxiga |
| Amgen INC. | $784.79 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $761.07 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $650.15 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.11 | 2021-2025 | Jardiance |
| Medtronic, INC. | $158.94 | 2025 | Mazor X System |
| Pfizer INC. | $110.56 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.40 | 2024-2025 | |
| Edwards Lifesciences Corporation | $102.00 | 2019-2021 | |
| Esperion Therapeutics, INC. | $91.20 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $87.25 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $81.48 | 2021 | |
| Gilead Sciences, INC. | $74.60 | 2019-2020 | |
| Stryker Corporation | $67.83 | 2023 | Xpress Ent Dilation System |
| Boston Scientific Corporation | $59.43 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $59.28 | 2021-2022 | |
| Livanova USA, INC. | $47.60 | 2019 | |
| Novo Nordisk INC | $38.63 | 2020-2023 | Rybelsus, Ozempic |
| Lexicon Pharmaceuticals, INC. | $24.91 | 2023 | Inpefa |
| Sanofi-Aventis U.S. LLC | $21.76 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.08 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.